Abstract: A semiconductor device according to one embodiment includes first and second conductors, a first insulator, and first and second contacts. The first conductor includes a first pad portion. The first pad portion includes first and second sub portions. Each of the first and second sub portions includes one and another end portions. The first sub portion is adjacent to the second pad portion. The second sub portion is adjacent to the first insulator. A length of the second sub portion of the first pad portion is less than a length of the first sub portion of the first pad portion.

Abstract: A semiconductor device according to one embodiment includes first and second conductors, a first insulator, and first and second contacts. The first conductor includes a first pad portion. The first pad portion includes first and second sub portions. Each of the first and second sub portions includes one and another end portions. The first sub portion is adjacent to the second pad portion. The second sub portion is adjacent to the first insulator. A length of the second sub portion of the first pad portion is less than a length of the first sub portion of the first pad portion.

Abstract: N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide and salts thereof are used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam or its salt in said pharmaceutical compositions after a stroke allows an improvement of the Acivities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients.

Abstract: N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide and salts thereof are used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam or its salt in said pharmaceutical compositions after a stroke allows an improvement of the Acivities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients.

Abstract: A method for aiding cerebral recovery following neurodegeneration, particularly after a stroke, in a mammal, by administration of nefiracetam is disclosed. This method of treatment allows an improvement in the recovery from stroke.

Abstract: A method for improving the disturbancies of Activities of Daily Living in post-stroke patients by early administration of nefiracetam after the stroke is disclosed. This method of treatment allows an improvement in the recovery from stroke.

Abstract: There is described a method for treating neurodegeneration, particularly after a stroke, in a mammal, by administration of nefiracetam. This method of treatment allows an improvement in the recovery from stroke.

Abstract: There is described a method for improving the disturbancies of Activities of the Daily Living in post-stroke patients by early administration of nefiracetam after the stroke. This method of treatment allows an improvement in the recovery from stroke.

Abstract: The present invention aims at providing a drug which is highly effective in improving decline of mental functions such as disorientation, which are the major symptoms of dementia such as Alzheimer type dementia or cerebrovascular dementia, as well as general side symptoms such as decreased spontaneity, contact disturbances, motivation, emotional disturbances, abnormal behaviors and disturbances in activity of daily living. The agent for improving dementia of the present invention comprises N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide or a salt thereof as an active ingredient.